#USA #Veeva Systems #Barcelona #Indero Research #RTSM Studies

Indero Commences 40th RTSM Study with Veeva Systems

Indero, previously known as Innovaderm Research, has recently achieved a significant milestone by launching its 40th RTSM (Randomized Trial Supply Management) study utilizing the advanced platform provided by Veeva Systems. This partnership is a testament to their commitment to improving clinical trial processes and enhancing operational efficiency. Through standardizing its procedures with Veeva RTSM, Indero aims to optimize its clinical study workflows and provide a seamless experience across various stakeholders.

Standardizing for Success

The adoption of Veeva RTSM has allowed Indero to reinforce its clinical trial operations by leveraging state-of-the-art technology and expert support. Eric Hardy, Senior Director of Biometrics at Indero, emphasized the positive impact of such standardization on their processes. He stated, “As we continue to optimize our clinical study operations, Veeva RTSM has fostered more efficient processes and closer collaboration, ensuring seamless execution.” This integration not only facilitates improved consistency across studies but also accelerates the overall process, making it quicker to bring new therapies to market.

The noteworthy achievement of launching the 40th RTSM study also reflects the ongoing collaboration and strategic partnership between Indero and Veeva Systems. Since the introduction of Veeva RTSM, Indero has worked hand-in-hand with Veeva to continuously refine and implement standardized processes to enhance the long-term success of their clinical studies.

Enhancing Clinical Trials

The use of Veeva’s unified RTSM approach provides Indero with increased long-term efficiency and reliability across its studies. As Steve Simmerman, General Manager of Veeva RTSM, commented, “With the enterprise-wide RTSM approach, Indero achieves greater long-term efficiency and reliability in its studies.” The collaborative efforts to standardize clinical processes not only accelerate study timelines but also demonstrate a streamlined approach that could lead the industry towards more effective and timely pharmaceutical development.

By enhancing these processes, Indero is positioned to better serve its sponsors, sites, and patients, making it a priority to deliver new therapies more quickly. This proactive strategy ensures that all involved parties can experience the benefits of faster access to advanced treatment options.

Looking Ahead

As Indero progresses toward optimizing its clinical study frameworks, the successful launch of its 40th RTSM study marks an important milestone. This achievement not only highlights the efficacy of Veeva RTSM in transforming clinical operations but also reflects Indero’s dedication to continuous improvement and innovation in the biopharmaceutical field.

For further information about Veeva's RTSM enterprise solutions, you can visit www.veeva.com/rtsm. As the leading provider of cloud software for the life sciences industry, Veeva aims to align the interests of its clients, employees, shareholders, and the industry at large—signifying its commitment to long-term sustainable practices.

Indero's continued efforts to embrace cutting-edge technology contribute to its mission of advancing healthcare through improved clinical trial methodologies. The journey doesn't end here; further optimizations and innovations are on the horizon as the team at Indero navigates the complexities of modern clinical research.